How about the best option, Partner with a BP for the licensing and milestone and royalty payments plus  a possible  M & A at the end of the trial only for Apabetalone for one indication for therapy combination with the SGLT2 inhibitor.  Leave the rest of the IP and all other indications for further partnering or licensing with other BP's .  Leaves alot more on the table for future valuation of the company.